Substance / Medication

Amprenavir

Overview

Active Ingredient
amprenavir
RxNorm CUI
228656

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
The influence of gastric motility on the intraluminal behavior of fosamprenavir.
Braeckmans Marlies, Brouwers Joachim, Masuy Imke et al. · Eur J Pharm Sci · 2020
PMID: 31682976RCT
Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers.
Jacobs Birgit S, Colbers Angela P H, Velthoven-Graafland Kirsten et al. · Int J Antimicrob Agents · 2014
PMID: 24929949RCT
Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.
Gruber Valerie A, Rainey Petrie M, Moody David E et al. · Clin Infect Dis · 2012
PMID: 22100576RCTFull text (PMC)
Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers.
Brüggemann Roger J M, van Luin Matthijs, Colbers Engelina P H et al. · J Antimicrob Chemother · 2010
PMID: 20667889RCT
Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
McRae Marypeace, Clay Patrick G, Anderson Peter L et al. · Pharmacotherapy · 2009
PMID: 19637947RCT
Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects.
Ford Susan L, Chen Ya-Chi, Lou Yu et al. · Antimicrob Agents Chemother · 2008
PMID: 18056271RCTFull text (PMC)
Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.
Wire Mary B, Baker Katherine L, Jones Lori S et al. · Antimicrob Agents Chemother · 2006
PMID: 16569890RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Amprenavir (substance)
SNOMED CT
387006009
UMLS CUI
C0754188
RxNorm CUI
228656

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.